After three-straight All-Star appearances from 2009-2012 that included winning league MVP honors in 2010, Rose could not stay on the court for long as a member of the Chicago Bulls.
Since suffering his second knee injury in 2013 Rose has not been able to get back to the skill level he once was at when he won MVP.
Rose played in 66 games last season for Chicago, his most since his 2011 MVP season, and the Knicks took a chance on his health by acquiring him on the eve of the National Basketball Association draft in June.
Rose tore his ACL in the 2012 playoffs, then missed the full 2012-13 season. He played in 130 of 164 games the past two seasons - averaging 18.0 points and 4.4 assists in 2016-17 - after missing 212 of 312 the previous four years with the Bulls. He ends it having played 64 games, having already missed 10 before Sunday's matinee against Boston and now sidelined for New York's final six.
Thus ends a star-crossed season that began with a rape trial and pretty much sucked in a way that only a Knicks season can suck.
Anti-allergy medicine EpiPen recall expands to US
Meridian Medical Technologies manufactures the devices, which Mylan Specialty distributes in the United States. The widening recall is yet another setback for Mylan in its quest to maintain EpiPen as a big-selling product.
However, his name did pop up at the trade deadline in a possible deal that would have sent him to the Minnesota Timberwolves in exchange for Ricky Rubio, per ESPN's Marc Stein.
Knee injuries have been a serious issue for Rose throughout his career.
The Knicks point guard's body has failed him again.
The Knicks are likely to move on from Carmelo Anthony this offseason as well, rebuilding in president Phil Jackson's effort to return the franchise to relevancy.